CSF1R and hereditary spastic paraplegia: We recently showed that targeting microglia using long-term oral administration of the CSF-1R inhibitor PLX3397 depletes microglia without obvious neurological side effects and significantly attenuates neuroinflammation-related neural damage in the CNS of a genetic model displaying features characteristic of progressive multiple sclerosis and hereditary spastic paraplegia [23, 24].